Cell-free protein expression, also called in vitro protein synthesis, involves the production of the desired recombinant proteins in cell lysates without using cell culture or living cells. Cell lysates produced via the breakdown and use of cellular components (eukaryotic or bacterial cells of humans or insects). Cell-free protein expression is carried out using different cell extracts such as those of E. coli (prokaryotic), rabbit reticulocytes, wheat germs eukaryotes), and insect cells. This system has many significant advantages over protein expression in living cells including the shorter duration of the process, expression of toxic proteins, isotopic labeling of proteins, optimization of protein complexes, incorporation of non-natural amino acids, optimization of protein production, and cost-effectiveness. Cell-free protein expression also allows the co-expression of multiple proteins and is easily employed for automation.
The global cell-free protein expression market is divided into the following product types on the basis of lysates used: mammalian, E. coli, wheat germs, and insect membrane. Among these, E. coli cell lysates are highly used. In terms of the expression mode, CFPS are categorized into the continuous and batch modes. The three major end-users of CFPS systems are the pharmaceutical & biotechnological industry, contract research institutes, and academic & research institutes, of which pharmaceutical companies are dominant, followed by contract research institutes.
The global CFPS market is driven by the key advantages of this system over in vivo protein synthesis such as the shorter duration required to receive the desired recombinant proteins, advanced applications in enzyme engineering, protein purification, and modification. Other factors projected to propel the market during the forecast period include the increasing demand for protein synthesis, rising activity of outsourcing pharmaceutical and biotechnological companies, and the growing number of research and academic institutes. New developments such as Protein Synthesis Using Recombinant Elements (PURE) offer opportunities for specialized applications such as in vitro protein evolution, protein micro-arrays, and protein labelling. The high cost of CFPS & reagents and low protein production rates are anticipated to restrict the global CFPS market.
Based on geography, global CFPS market is distributed over North America, Europe, Asia Pacific, Middle East & Africa, and Latin America. North America dominates the market owing to the high expenditure on R&D activities and increasing demand for protein synthesis in the region. Europe and APAC are likely to display high growth rates during the forecast period as a result of the surge in R&D, biopharmaceutical companies, and demand for recombinant proteins.
Key players operating in the global CFPS market include New England Biolabs, Inc., TAKARA BIO INC., Thermo Fisher Scientific Inc., Promega Corporation., CellFree Sciences Co., biotechrabbit GmbH, Bioneer Corporation, Jena Bioscience GmbH, and Cube Biotech GmbH etc. Among these, Thermo Fisher Scientific Inc., biotechrabbit GmbH, and New England Biolabs, Inc. are the leaders. The New England Biolabs, Inc. has developed the technology PURE for CFPS and is promoting its use and application across the globe.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.